JP2022545167A - Tgfベータ結合ドメインを含むキメラサイトカイン受容体 - Google Patents
Tgfベータ結合ドメインを含むキメラサイトカイン受容体 Download PDFInfo
- Publication number
- JP2022545167A JP2022545167A JP2022505440A JP2022505440A JP2022545167A JP 2022545167 A JP2022545167 A JP 2022545167A JP 2022505440 A JP2022505440 A JP 2022505440A JP 2022505440 A JP2022505440 A JP 2022505440A JP 2022545167 A JP2022545167 A JP 2022545167A
- Authority
- JP
- Japan
- Prior art keywords
- chimeric cytokine
- cytokine receptor
- seq
- tgf
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4204—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962894658P | 2019-08-30 | 2019-08-30 | |
| US62/894,658 | 2019-08-30 | ||
| US202063053322P | 2020-07-17 | 2020-07-17 | |
| US63/053,322 | 2020-07-17 | ||
| PCT/US2020/048402 WO2021041806A1 (en) | 2019-08-30 | 2020-08-28 | Chimeric cytokine receptors comprising tgf beta binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022545167A true JP2022545167A (ja) | 2022-10-26 |
| JP2022545167A5 JP2022545167A5 (cg-RX-API-DMAC7.html) | 2023-09-01 |
Family
ID=72521701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505440A Pending JP2022545167A (ja) | 2019-08-30 | 2020-08-28 | Tgfベータ結合ドメインを含むキメラサイトカイン受容体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12528856B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4021582A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022545167A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220052919A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114341193A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020336131B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022003553A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3145614A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290960A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022002297A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021041806A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL285941B1 (en) * | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
| WO2022020456A2 (en) | 2020-07-21 | 2022-01-27 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
| CN117120075A (zh) * | 2021-02-17 | 2023-11-24 | 库拉治疗股份有限公司 | 抗病原体白细胞介素-TGF-β受体融合多肽 |
| CA3217252A1 (en) * | 2021-04-19 | 2022-10-27 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and uses thereof in cellular therapies |
| CA3230292A1 (en) | 2021-08-27 | 2023-03-02 | Theranotics Co., Ltd. | Bispecific molecule specifically binding to b7-h3 and tgfb and uses thereof |
| CN115873802A (zh) * | 2021-09-29 | 2023-03-31 | 亘喜生物科技(上海)有限公司 | 嵌合抗原受体免疫细胞及其制法和应用 |
| US20250041336A1 (en) * | 2021-09-29 | 2025-02-06 | Vita Therapeutics, Inc. | Methods and compositions for treating cancer with engineered cells |
| JP2024539013A (ja) * | 2021-10-20 | 2024-10-28 | フェイト セラピューティクス,インコーポレイティド | 固形腫瘍における同種異系養子細胞療法のためのエフェクター細胞及びその使用 |
| GB202117298D0 (en) * | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| EP4479068A4 (en) * | 2022-02-18 | 2026-01-07 | Univ California | ENHANCED MULTIPLICATION AND FUNCTION OF PRIMARY HUMAN NK CELLS BY A CHIMERICAL CYTOKINE RECEPTOR |
| EP4499680A1 (en) * | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| GB202301421D0 (en) * | 2023-02-01 | 2023-03-15 | Univ Oslo Hf | Switch receptor for use in adoptive cell therapy |
| CN116284449B (zh) * | 2023-02-27 | 2024-11-19 | 深圳市先康达生命科学有限公司 | 增强型TGF-βR嵌合受体及其应用 |
| EP4724086A1 (en) * | 2023-06-06 | 2026-04-15 | F. Hoffmann-La Roche AG | Switch receptors |
| CN121532650A (zh) | 2023-06-20 | 2026-02-13 | 艾洛基治疗公司 | 工程化的细胞的检测方法 |
| KR20260105764A (ko) | 2023-10-30 | 2026-07-07 | 알로젠 테라퓨틱스 인코포레이티드 | 조작된 세포 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016520302A (ja) * | 2013-04-17 | 2016-07-14 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | 免疫抑制TGF−βシグナルコンバーター |
| WO2017103596A1 (en) * | 2015-12-15 | 2017-06-22 | Cellular Therapeutics Ltd | Cells expressing recombinant growth factor receptors |
| WO2018038945A1 (en) * | 2016-08-26 | 2018-03-01 | Baylor College Of Medicine | Constitutively active cytokine receptors for cell therapy |
| WO2018094244A1 (en) * | 2016-11-17 | 2018-05-24 | Bluebird Bio, Inc. | TGFβ SIGNAL CONVERTOR |
| JP2019500012A (ja) * | 2015-10-30 | 2019-01-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
| WO2019055946A1 (en) * | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF |
| WO2019079520A2 (en) * | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL114825A0 (en) | 1994-08-04 | 1995-12-08 | Regeneron Pharma | Rtk/cytokine receptor chimeras |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO1998002558A2 (en) | 1996-07-17 | 1998-01-22 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
| EP1033374B1 (en) | 1997-11-26 | 2012-08-01 | Chugai Seiyaku Kabushiki Kaisha | Signal sequence trapping method |
| WO2007075899A2 (en) | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| AU2009292996B2 (en) | 2008-09-22 | 2015-04-23 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters |
| WO2011069004A1 (en) | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| EP2694640B1 (en) | 2011-04-08 | 2017-10-18 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| EP3569253A1 (en) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| AU2015330017A1 (en) | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| DK3227339T3 (da) | 2014-12-05 | 2022-01-10 | Memorial Sloan Kettering Cancer Center | Kimæriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf |
| EP3234145B1 (en) | 2014-12-15 | 2019-06-05 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| CA2974998C (en) | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| TWI700298B (zh) | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向b細胞成熟抗原之嵌合型抗原受體類 |
| WO2016168612A1 (en) | 2015-04-15 | 2016-10-20 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| WO2018161064A1 (en) | 2017-03-03 | 2018-09-07 | F1 Oncology, Inc. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| CN106399255B (zh) | 2016-04-13 | 2019-10-18 | 阿思科力(苏州)生物科技有限公司 | Pd-1 car-t细胞及其制备方法和应用 |
| WO2018104473A1 (en) | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| GB201702617D0 (en) | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| AU2019227979B2 (en) | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| CN112533942A (zh) | 2018-06-01 | 2021-03-19 | 华盛顿大学 | 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 |
| CN112368298A (zh) | 2018-06-22 | 2021-02-12 | 凯德药业股份有限公司 | 嵌合跨膜蛋白及其用途 |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| IL328846A (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases |
| IL285941B1 (en) * | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
-
2020
- 2020-08-28 BR BR112022003553A patent/BR112022003553A2/pt unknown
- 2020-08-28 US US17/005,757 patent/US12528856B2/en active Active
- 2020-08-28 CA CA3145614A patent/CA3145614A1/en active Pending
- 2020-08-28 JP JP2022505440A patent/JP2022545167A/ja active Pending
- 2020-08-28 EP EP20772464.2A patent/EP4021582A1/en active Pending
- 2020-08-28 KR KR1020227004538A patent/KR20220052919A/ko active Pending
- 2020-08-28 WO PCT/US2020/048402 patent/WO2021041806A1/en not_active Ceased
- 2020-08-28 MX MX2022002297A patent/MX2022002297A/es unknown
- 2020-08-28 AU AU2020336131A patent/AU2020336131B2/en active Active
- 2020-08-28 CN CN202080061119.3A patent/CN114341193A/zh active Pending
-
2022
- 2022-02-27 IL IL290960A patent/IL290960A/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016520302A (ja) * | 2013-04-17 | 2016-07-14 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | 免疫抑制TGF−βシグナルコンバーター |
| JP2019500012A (ja) * | 2015-10-30 | 2019-01-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 |
| WO2017103596A1 (en) * | 2015-12-15 | 2017-06-22 | Cellular Therapeutics Ltd | Cells expressing recombinant growth factor receptors |
| WO2018038945A1 (en) * | 2016-08-26 | 2018-03-01 | Baylor College Of Medicine | Constitutively active cytokine receptors for cell therapy |
| WO2018094244A1 (en) * | 2016-11-17 | 2018-05-24 | Bluebird Bio, Inc. | TGFβ SIGNAL CONVERTOR |
| WO2019055946A1 (en) * | 2017-09-18 | 2019-03-21 | F1 Oncology, Inc. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF |
| WO2019079520A2 (en) * | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF |
Non-Patent Citations (3)
| Title |
|---|
| HIROSHI MIYAZAKI, "THE THROMBOPOIETIN RECEPTOR", JAPANESE JOURNAL OF THROMBOSIS AND HEMOSTASIS, vol. 26, no. 1, JPN6024044825, 2015, pages 35 - 41, ISSN: 0005747732 * |
| JEAN-PHILIPPE DEFOUR ET AL.: ""Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 7, JPN6024044826, 28 January 2013 (2013-01-28), pages 2540 - 2545, ISSN: 0005747731 * |
| KOICHIRO SAKA ET AL.: ""Activation of target signal transducers utilizing chimeric receptors with signaling‐molecule bind", BIOTECHNOLOGY AND BIOENGINEERING, vol. 109, no. 6, JPN6024044827, 7 January 2012 (2012-01-07), pages 1528 - 1537, ISSN: 0005747730 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020336131A1 (en) | 2022-02-24 |
| MX2022002297A (es) | 2022-03-25 |
| IL290960A (en) | 2022-04-01 |
| KR20220052919A (ko) | 2022-04-28 |
| WO2021041806A1 (en) | 2021-03-04 |
| EP4021582A1 (en) | 2022-07-06 |
| CN114341193A (zh) | 2022-04-12 |
| CA3145614A1 (en) | 2021-03-04 |
| BR112022003553A2 (pt) | 2022-05-24 |
| US20210061881A1 (en) | 2021-03-04 |
| AU2020336131B2 (en) | 2025-09-11 |
| US12528856B2 (en) | 2026-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7633937B2 (ja) | Pd-1外部ドメインを担持するキメラサイトカイン受容体 | |
| US12528856B2 (en) | Chimeric cytokine receptors comprising TGF β binding domains | |
| JP7793667B2 (ja) | 誘導性キメラサイトカイン受容体 | |
| JP7667086B2 (ja) | 構成的に活性なキメラサイトカイン受容体 | |
| TWI894211B (zh) | 具有增強活性之bcma car-t細胞 | |
| CA2995632C (en) | Chimeric antigen receptors with integrated controllable functions | |
| KR20210013691A (ko) | 수정된 링커 도메인을 갖는 키메라 항원 수용체 및 그 용도 | |
| TW202317634A (zh) | 抗EGFRviii抗體、多肽、表現前述多肽之細胞、含有前述細胞之醫藥組成物、前述細胞之製造方法、及含有編碼前述多肽之鹼基序列之聚核苷酸或載體 | |
| RU2842294C1 (ru) | Химерные цитокиновые рецепторы, содержащие домены, связывающие tgf-бета | |
| RU2824672C2 (ru) | Конститутивно активные химерные цитокиновые рецепторы | |
| RU2826155C2 (ru) | Индуцибельные химерные цитокиновые рецепторы | |
| HK40063003B (en) | Constitutively active chimeric cytokine receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230824 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230824 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250402 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250710 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251008 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251208 |